106548-41-8Relevant articles and documents
Sensitized electroluminescence on mesoporous oxide Semiconductor films
Athanassov, Yordan,Rotzinger, Francì§ois P.,Peì?chy, Peì?ter,Graì?tzel, Michael
, p. 2558 - 2563 (1997)
Forward biasing of a mesoporous TiO2 (anatase) film whose surface is derivatized with a monolayer of the phosphonated ruthenium bipyridyl complex RuL2La?2 with L = 4,7-diphenyl-1,10-phenanthroline and La?2 = 2,2a?2-bipyridine-4,4a?2-
Increased photocatalytic activity in Ru(II),Rh(III) supramolecular bimetallic complexes with terminal ligand substitution
Sayre, Hannah J.,White, Travis A.,Brewer, Karen J.
, p. 89 - 96 (2017)
Three new Ru(II),Rh(III) supramolecular bimetallic complexes of the design [(Ph2phen)2Ru(dpp)RhCl2(R2-bpy)](PF6)3(R?=?CH3(Ru-Rh(Me2bpy)), H (Ru-Rh(bpy)), or COOCH3(Ru-Rh(dmeb)); Ph2phen?=?4,7-diphenyl-1,10-phenanthroline; dpp?=?2,3-bis(2-pyridyl)pyrazine; dmeb?=?4,4′-dimethyl ester-2,2′-bipyridine; bpy?=?2,2′-bipyridine; Me2bpy?=?4,4′-dimethyl-2,2′-bipyridine) have been synthesized and analyzed to determine the impact that the polypyridyl terminal ligand (TL) coordinated to the cis-dihalide rhodium(III) metal center has on the photocatalytic activity for water reduction. The bimetallic complexes demonstrate that a correlation exists between the σ-donating ability of the substituted bipyridine ligand, the rate of chloride dissociation upon electrochemical reduction and the activity towards photocatalytic hydrogen production. The weaker σ-donating –COOCH3substituent in Ru-Rh(dmeb) increases the rate constant for Cl?dissociation (k?Cl?=?0.7?s?1) and the amount of H2produced photocatalytically (37?±?4?μmol H2, 63?±?7 turnovers after 20?h; turnovers?=?mol H2/mol photocatalyst) when compared to –H and –CH3substituted complexes Ru-Rh(bpy) (k?Cl?=?0.2?s?1, 21?±?2?μmol H2, 35?±?3 turnovers) and Ru-Rh(Me2bpy) (k?Cl?=?0.2?s?1, 18?±?2?μmol H2, 30?±?4 turnovers), respectively. Varied catalytic activity with respect to the σ-donor capacity of the Rh-TL is attributed to the relative ease of ligand dissociation and the ability to afford rapid electron collection at the Rh metal center.
Mixed-Ligand Complexes of Ruthenium(II): Factors Governing Binding to DNA
Pyle, A. M.,Rehmann, J. P.,Meshoyrer, R.,Kumar, C. V.,Turro, N. J.,et al.
, p. 3051 - 3058 (1989)
Binding and spectroscopic parameters for a series of mixed-ligand complexes on binding to DNA have been determined.The application of mixed-ligand complexes permits the variation in geometry, size, hydrophobicity, and hydrogen-bonding ability by systemati
Ruthenium-artesunate complex as well as preparation method and application thereof
-
Paragraph 0030-0031, (2021/04/17)
The invention discloses a ruthenium-artesunate complex as well as a preparation method and an application thereof, the ruthenium-artesunate complex can improve the uptake of artesunate by cells by utilizing the ruthenium complex, and after entering the cells, the ruthenium complex and artesunate synergistically play an anti-tumor role. The anti-tumor activity of the ruthenium-artesunate complex is researched. the ruthenium-artesunate complex has high antitumor activity, and compared with a traditional organic small molecule, the complex has the multi-coordination configuration, and can modify different ligands so as to achieve specific binding of the complex with a corresponding substrate.
Targeted ovarian cancer ruthenium-LHRH coupling diagnosis and treatment probe as well as preparation method and application thereof
-
Paragraph 0022; 0028, (2021/05/29)
The invention relates to a ruthenium-LHRH coupling diagnosis and treatment probe for targeting ovarian cancer as well as a preparation method and application of the ruthenium-LHRH coupling diagnosis and treatment probe. The structural formula of the ruthe
Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as a Potential Chemotherapeutic Agent: From Synthesis to in Vivo Studies
Notaro, Anna,Frei, Angelo,Rubbiani, Riccardo,Jakubaszek, Marta,Basu, Uttara,Koch, Severin,Mari, Cristina,Dotou, Mazzarine,Blacque, Olivier,Gouyon, Jérémie,Bedioui, Fethi,Rotthowe, Nils,Winter, Rainer F.,Goud, Bruno,Ferrari, Stefano,Tharaud, Micka?l,?ezá?ová, Martina,Humajová, Jana,Tom?ík, Pavel,Gasser, Gilles
, p. 5568 - 5584 (2020/06/17)
Chemotherapy remains one of the dominant treatments to cure cancer. However, due to the many inherent drawbacks, there is a search for new chemotherapeutic drugs. Many classes of compounds have been investigated over the years to discover new targets and synergistic mechanisms of action including multicellular targets. In this work, we designed a new chemotherapeutic drug candidate against cancer, namely, [Ru(DIP)2(sq)](PF6) (Ru-sq) (DIP = 4,7-diphenyl-1,10-phenanthroline; sq = semiquinonate ligand). The aim was to combine the great potential expressed by Ru(II) polypyridyl complexes and the singular redox and biological properties associated with the catecholate moiety. Experimental evidence (e.g., X-ray crystallography, electron paramagnetic resonance, electrochemistry) demonstrates that the semiquinonate is the preferred oxidation state of the dioxo ligand in this complex. The biological activity of Ru-sq was then scrutinized in vitro and in vivo, and the results highlight the promising potential of this complex as a chemotherapeutic agent against cancer.
